NCT06177249 (rabies) is a Phase 3 clinical trial of Control vaccine in Rabies Human, sponsored by Hualan Biological Bacterin Co. Ltd..

Who is sponsoring NCT06177249?

NCT06177249 is sponsored by Hualan Biological Bacterin Co. Ltd..

What drugs are being tested in NCT06177249?

Interventions in NCT06177249: Control vaccine, Experimental vaccine.

What condition does NCT06177249 study?

NCT06177249 studies Rabies Human.

Is NCT06177249 still recruiting?

NCT06177249 is currently completed. Last updated 20 December 2023.

Last reviewed 2023-12-20 · How we verify

NCT06177249: rabies

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)

Completed Phase 3 Last updated 20 December 2023

What this trial tests

Phase 3 trial testing Control vaccine in Rabies Human in 1,956 participants. Completed in 1 May 2016.

Timeline

15 March 2015

Primary endpoint
16 December 2015

1 May 2016

Quick facts

Lead sponsor	Hualan Biological Bacterin Co. Ltd.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	health services research
Enrollment	1,956
Start date	15 March 2015
Primary completion	16 December 2015
Estimated completion	1 May 2016
Sites	1 location across China

Drugs / interventions tested

Control vaccine — full drug profile →
Experimental vaccine — full drug profile →

Conditions studied

Rabies Human — all drugs for Rabies Human →

Sponsor

Hualan Biological Bacterin Co. Ltd. — full company profile →

Who can join

Adults 9 to 65, any sex, with Rabies Human. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and immunogenicity of lyophilized human rabies vaccine (Vero cell) developed by Hualan Biological in healthy people aged 9 to 65 years with two different immunization schedules.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Control vaccine

Trials testing the same drug.

NCT05960097 — A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults · Phase 2 · completed

Other Hualan Biological Bacterin Co. Ltd. trials

Trials by the same sponsor.

NCT06334510 — Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations. · completed
NCT06095947 — Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years · completed
NCT03196661 — Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06177249 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hualan Biological Bacterin Co. Ltd.
Last refreshed: 20 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06177249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing